NattoPharma ASA announced the following management changes to its organization: Daniel Rosenbaum, who has been serving as COO of NattoPharma for the last 12 months, will now assume the role of CEO. Dr. Hogne Vik, who has been serving in the role of CEO of NattoPharma since 2012, will now assume the role of Chief Medical Officer. As CMO, Dr. Vik will work with the global medical community to increase advocacy of MenaQ7 and will guide the company's continuing clinical research initiatives.

Kjetil Ramsøy will join the company, effective January 1, 2016, in the role of Chief Financial Officer. Mr. Ramsøy comes to NattoPharma from Seabed GeoSolutions, where he served as CFO. Having worked in both Scandinavia and the United States, he brings both global financial and public company experience to NattoPharma.

William Sommer joins the company to serve as Vice President, Global Development and Regulatory. Prior to joining NattoPharma, Mr. Sommer led the global formulations group at FMC Chemical Corporation. A chemical engineer by training, Mr. Sommer has more than 20 years' experience working in development, specialty chemical manufacturing, and regulated industries.